Science & academia

This archive covers milestones and breakthroughs from the scientific and academic world — researchers, universities, and institutions whose work advances human knowledge. Stories here highlight discoveries, studies, and scholarly efforts that point toward a better future.

Aerial view of container ship

Decarbonization containers turn 78% of marine emissions into limestone in new pilot

By / / Good news links

A remarkable pilot project installed on a 787-ft. container ship has proven it’s possible to capture emissions from the smokestacks of cargo ships with 78% efficiency and convert the CO2 into limestone pebbles, which can be offloaded and sold. London startup Seabound, funded by a US$1.5-million grant from the UK Government, partnered up with global shipping company Lomar to install the carbon capture equipment on one of its older and dirtier-burning ships, a medium-sized vessel capable of carrying more than 3,200 shipping containers.

Assortment of pills, for article on AI antidepressant prediction

Novel AI model rapidly determines if an antidepressant will work

By / / Good News For Humankind

Antidepressant treatment has long meant weeks of waiting, side effects, and uncertainty — and for around 60% of people with depression, the first medication simply doesn’t work. Dutch researchers developed an AI model that predicts within one week whether sertraline will help a patient by reading brain blood flow patterns and early symptom changes, potentially allowing clinicians to pivot sooner for those unlikely to respond. The model is limited to sertraline and requires further validation before clinical use — but it points toward a future where prescribing depression treatment looks less like guesswork and more like precision medicine.

Depiction of nerve cells, for article on non-opioid compound

Researchers discover an effective non-opioid treatment for nerve pain

By / / Good News For Humankind

Nerve pain affects an estimated one in ten adults in the U.S., and for many, nothing currently available offers real relief. A new compound called FEM-1689 reduced pain hypersensitivity in mice with diabetic and chemotherapy-induced neuropathy, working through a receptor entirely separate from opioid pathways and sidestepping addiction risk. The same cellular effect was observed in human neurons in the lab. All results remain pre-clinical, and many promising compounds fail before reaching patients. But the mechanistic clarity here puts a genuinely safer treatment for one of medicine’s most stubborn problems on much firmer ground.

Chromosomes, for article on CRISPR gene therapy hereditary angioedema

Gene therapy hailed as ‘medical magic wand’ for hereditary swelling disorder

By / / Good News For Humankind

CRISPR gene editing has freed ten patients with hereditary angioedema from the sudden, sometimes life-threatening swelling attacks that shaped their daily lives, with several remaining attack-free for 18 months and counting after a single infusion. The therapy works by switching off a gene in liver cells, stopping the painful chain reaction at its source rather than just managing symptoms. One participant who used to have attacks every three weeks has needed no medication since. Doctors are now recruiting for a phase-three trial, building on the same Nobel-winning technology that recently produced an approved cure for sickle cell disease. For a rare condition long defined by unpredictability and fear, it’s a glimpse of what gene editing could mean for millions living with inherited illness worldwide.

Person having blood drawn, for article on Alzheimer's blood test

Breakthrough Alzheimer’s blood test could detect disease 15 years before symptoms emerge

By / / Good News For Humankind

A simple Alzheimer’s blood test trialed in Sweden can detect the disease’s biological signs up to 15 years before symptoms appear, matching the accuracy of a spinal tap in a study of 786 people. The test measures p-tau217, a protein that builds up in the blood as Alzheimer’s-related changes unfold in the brain. Researchers suggest it could one day be as routine as a cholesterol check for anyone over 50, replacing painful lumbar punctures and hard-to-access specialist scans. With one in three people born in the U.K. today expected to develop dementia, catching the disease early — while there’s still time to intervene — could transform how the world confronts one of its most feared illnesses.

Person receiving shot in the arm, for article on melanoma cancer vaccine

Cancer vaccine with minimal side effects nearing Phase 3 clinical trials

By / / Good News For Humankind

A personalized cancer vaccine is heading into Phase 3 trials after a remarkable Phase 2 result: nearly 95% of advanced melanoma patients who received only the vaccine were still alive three years later. What makes Dr. Thomas Wagner’s TLPO vaccine so striking isn’t just the survival numbers — it’s the gentleness. Patients report little more than a sore arm and mild fatigue, a world away from the dread of chemotherapy. The vaccine is made from each patient’s own tumor cells, teaching their immune system to recognize cancer as the threat it is. If the larger trial holds up, it could reshape how we think about treating cancer everywhere — not as something to endure, but something to outsmart.

Artist's concept of a solar power satellite in place, for article on space solar power

First ever space-to-Earth solar power mission succeeds

By / / Good News For Humankind

Space-based solar power just cleared a milestone scientists have been chasing since the 1970s: a Caltech satellite spent a year in orbit, collected sunlight, and beamed it wirelessly back to a ground receiver on Earth. The SSPD-1 mission completed all three of its planned experiments, including testing an origami-inspired panel that unfolds without hinges and a purpose-built microwave transmitter. The appeal is simple — above the atmosphere, the Sun never sets, no clouds get in the way, and power could flow around the clock. Caltech’s team is honest that commercial-scale space solar is still years off, with cost and radiation durability to solve. But moving this idea from whiteboard to working demonstration brings humanity a real step closer to truly continuous clean energy.

A family grocery shopping together for an article about consumption poverty in the U.S.

U.S. consumption poverty has fallen 27 percentage points since 1980

By / / Good News For Humankind

Consumption poverty in the United States has fallen dramatically since 1980, according to a major new study from the University of Notre Dame. Researchers found the poverty rate dropped 27 percentage points when measured by what families actually spend rather than what they report earning. The official income-based measure, by contrast, showed only a 1.5 percentage point decline over the same period. The findings suggest decades of policy investment in Social Security, tax credits, and safety net programs have produced far greater results than conventional statistics indicate.

Person receiving nasal spray, for article on intranasal COVID-19 vaccine

Novel nasal COVID-19 vaccine offers longer, better immunity than jabs

By / / Good News For Humankind

A nasal COVID-19 vaccine developed at Duke-NUS Medical School in Singapore is showing real promise: in hamster studies, it produced more central memory T cells than standard injections, hinting at protection that could last considerably longer. By delivering the vaccine right where the virus enters the body, researchers also saw stronger antibody responses against newly emerging variants. The team has filed a patent that covers other respiratory pathogens too, opening doors for future flu and RSV vaccines. Human trials are still ahead, but for anyone weary of frequent boosters — especially elderly and immunocompromised people — a needle-free shot offering broader, longer protection could meaningfully reshape how the world lives alongside evolving respiratory viruses.

Cancer cells, for article on multi-cancer blood test

New protein test can detect 18 early stage cancers, scientists say

By / / Good News For Humankind

A new blood test can screen for 18 different cancers at once — covering every major organ in the body — using a single ordinary blood draw. Researchers at U.S. biotech firm Novelna found the test caught 93% of earliest-stage cancers in male samples and 84% in female samples, while also pinpointing which organ the cancer came from in more than 80% of cases. Instead of hunting for tumor DNA, the team analyzed proteins in blood plasma, picking up faint signals before a tumor does visible damage. Larger studies are still needed before it reaches clinics, but a cheap, accurate, broad screening tool would be a quiet revolution for global health — especially in places where late diagnosis is still the norm.